Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRD4 Inhibition alleviates sepsis-associated acute kidney injury via suppression of NOX4-mediated oxidative stress and inflammation.

Cell death discovery·2026
Same author

Elevated SLC1A5 links to inflamed endothelial cells and proteinuria in membranous nephropathy patients.

PeerJ·2025
Same author

B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China.

Frontiers in immunology·2025
Same author

Efficacy and safety of tacrolimus versus cyclophosphamide therapy for Henoch-Schönlein purpura nephritis in children: A systematic review.

Medicine·2025
Same author

Glomerular mesangial derived extracellular vesicles deteriorate diabetic kidney disease via miR-3147/PRKAR2B axis.

Renal failure·2025
Same author

<i>MYDGF</i> Regulates Apoptotic Signaling to Mitigate Renal Ischemia-Reperfusion Injury and Enhance Chemotherapy Sensitivity.

Cancer biotherapy & radiopharmaceuticals·2025

Related Experiment Video

Updated: May 10, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

Simvastatin increases ADAMTS13 expression in podocytes.

Lei Shen1, Guoyuan Lu, Ningzheng Dong

  • 1Department of Nephrology, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, China.

Thrombosis Research
|July 3, 2013
PubMed
Summary

Simvastatin increases ADAMTS13 expression in kidney podocytes, potentially enhancing its antithrombotic effects. This study also reveals how inflammatory cytokines impact ADAMTS13 levels in these cells.

Keywords:
3-hydroxy-3-methylglutaryl coenzyme AA disintegrin-like and metalloprotease with thrombospondin type 1 repeats 13ADAMTS13HMG-CoAIL-4IL-6TNF-αTTPVWFinterleukin-4interleukin-6podocytesimvastatinthrombotic thrombocytopenic purpuratumor necrosis factor-αvon Willebrand factor

Related Experiment Videos

Last Updated: May 10, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

Area of Science:

  • Nephrology
  • Cardiovascular Research
  • Molecular Biology

Background:

  • ADAMTS13 (a von Willebrand factor-cleaving protease) deficiency causes thrombotic thrombocytopenic purpura.
  • ADAMTS13 is expressed in kidney podocytes, in addition to liver and endothelial cells.
  • Simvastatin, a statin, exhibits anti-inflammatory and antithrombotic properties.

Purpose of the Study:

  • To investigate the effect of simvastatin on ADAMTS13 expression in podocytes.
  • To determine how inflammatory cytokines (TNF-α, IL-4, IL-6) influence ADAMTS13 expression in podocytes.
  • To explore simvastatin's potential to counteract cytokine-induced suppression of ADAMTS13.

Main Methods:

  • Utilized a mouse podocyte cell line.
  • Measured ADAMTS13 mRNA and protein levels using real-time PCR and Western blotting.
  • Investigated the effects of TNF-α, IL-4, IL-6, and simvastatin on podocyte ADAMTS13 expression.

Main Results:

  • Simvastatin significantly upregulated ADAMTS13 mRNA and protein in podocytes.
  • IL-6 decreased ADAMTS13 expression, while TNF-α had no significant effect.
  • IL-4 reduced ADAMTS13 mRNA but not protein levels; simvastatin reversed IL-6's inhibitory effect.

Conclusions:

  • Simvastatin dose-dependently increases ADAMTS13 expression in podocytes, contributing to statin's antithrombotic activity.
  • Inflammatory cytokines differentially affect ADAMTS13 mRNA and protein levels in podocytes.
  • Podocyte ADAMTS13 regulation by simvastatin and cytokines has implications for kidney and cardiovascular health.